A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction

Monga, Ash; Tracey, M. R.; Subbaroyan, Jeyakumar

doi:10.1007/s00192-012-1691-5

Cited by 42 publications

(26 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6][7][8][9] The mechanism of action is not entirely clear; however, inhibition of afferent signals presumably interrupts inappropriate detrusor contractions. 18,19 Although originally not thought to be a promising treatment option for patients with neurogenic bladder disorders, more recent studies suggest that these patients can benefit from SNM and up to 68% of patients in the test phase and 92% of patients in the permanent SNM phase can be successfully treated; 10,11 we report similar success rates (56.5 and 92.3%, respectively).…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6] Many patients have achieved significant improvement in lower urinary tract symptoms and bowel disorders, such as fecal incontinence and constipation. 5,[7][8][9] Originally, SNM was not considered as an option for neurogenic lower urinary tract dysfunction (LUTD); however, some studies now suggest that SNM is also effective in this group of patients. 10,11 The aim of this retrospective study was to assess the clinical effects of SNM on patients with neurogenic bladder and/or bowel dysfunction who had multiple symptoms secondary to spinal cord disease or injury.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease

Chen

Liu

2014

Spinal Cord

View full text Add to dashboard Cite

Study design: Retrospective case series. Objectives: The primary aim was to assess the clinical effects of sacral neuromodulation (SNM) for neurogenic bladder and/or bowel dysfunction with multiple symptoms secondary to spinal cord disease or injury. Setting: Beijing, China. Methods: Between 2011 and 2013, 23 patients with multiple bladder and/or bowel problems secondary to spinal cord disease or injury were treated with a preliminary test SNM. If at least 50% clinical improvement occurred, then the patient underwent a permanent SNM procedure. We evaluated the patients using a bladder diary, post-void residual volume measurement and the Wexner questionnaire score for constipation before the test phase, during the test phase and after the permanent SNM. Results: In the test phase, the rate of improvement in dysuria (29.4%) was significantly lower than urgency frequency (64.7%), urinary incontinence (69.2%) and constipation (75.0%). An implant was performed in 13 (56.5%) patients, including 4 patients who still used intermittent catheterization to exclude urine after permanent SNM because the symptom of dysuria could not be improved significantly and 1 patient who achieved X50% improvement in lower urinary tract dysfunction but not in constipation. During follow-up (17.5 ± 2.0 months), 1 patient (7.7%) failed and 1 patient had bilateral vesicoureteral reflux. Conclusion: Chronic SNM cannot always resolve all the bladder and bowel symptoms secondary to spinal cord disease or injury, but combined with other treatments may help improve multiple symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease

Chen

Liu

2014

Spinal Cord

View full text Add to dashboard Cite

show abstract

“…While the reported success rates for subjects who received the implantation varied between 60% and 100%, an intention-totreat (ITT) analysis in a recent systematic review revealed success rates between 21% and 48% for one-stage implantation with PNE and 75% to 80% for two-stage implantation. 18 A recent prospective multicentre trial reported 36-month data using the two-stage technique. 19 Of 340 patients who received stimulation, 272 had the permanent implant.…”

Section: Sacral Neuromodulationmentioning

confidence: 99%

Managing overactive bladder in primary care

Robinson¹,

Belal²,

Granitsiotis³

et al. 2017

Trends Urol & Men's Health

View full text Add to dashboard Cite

O veractive bladder (OAB) is the term used to describe the symptom complex of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology. 1 HOW COMMON IS OAB?Epidemiological studies from North America have reported a prevalence of OAB in women of 16.9%, increasing with age to 30.9% in those over the age of 65 years. 2 Further data from Europe have shown the overall prevalence in men and women over the age of 40 years to be 16.6%. 3 Frequency was the most commonly reported symptom (85%), while 54% complained of urgency and 36% of urgency incontinence. The European Prospective Investigation into Cancer and Nutrition (EPIC) study, a cross-sectional telephone survey conducted in Canada and four European countries including the UK, utilised the International Continence Society terminology (more specific for the current OAB definition) and found the prevalence of OAB to be 12.8% in women and 10.8% in men.

show abstract

“…Recently, electrical stimulation has been used to treat bladder disorders, especially for urinary retention and incontinence and the efficacy is promising [11, 12]. The electrical stimulations mostly used were transcutaneous electrical stimulation (TENS), percutaneous tibal nerve stimulation (PTNS) and sacral neuromodulation (SNM).…”

Section: Introductionmentioning

confidence: 99%

Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial

Sun

Wang

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundClass III radical hysterectomy (RH III)_plus pelvic lymphadenectomy is the standard surgery for early stage cervical cancer (CC) patients, the 5 year survival rate is about 90%, but pelvic floor disorders especially bladder dysfunction are common due to damaged vessels and nerve fibers following surgery. Transcutaneous electrical stimulation (TENS) treatment has been used to treat bladder disorders for many years, but its effect on cervical cancer patients, the best treatment time point and stimulated protocol, had never been assessed. The aim of this study is to investigate the efficacy of TENS treatment on lower urinary tract symptoms (LUTS) after RH III in CC patients.Methods/DesignThe study will be conducted as a clinical, multicentre, randomised controlled trial with balanced randomisation (1:1). The planned sample size is 208 participants (at 1:1 ratio, 104 subjects in each group). At 5–7 days after RH III, patients are screened according to operative and pathological findings. Enrolled participants are randomised into an intervention group (TENS plus conventional clinical care) or control group (conventional clinical care), with stratification by menopausal status (menopause vs. non-menopause) and surgical modality (laparoscopic RH or abdominal RH). Participants in both groups will be followed up at 14 days, 21 days, 28 days, 3 months, 6 months, 12 months, 18 months and 24 months after surgery. The primary endpoint is improvement rate of urination function which is defined as recovery (residual urine ≤50 ml) or improvement (residual urine 50–100 ml). Secondary endpoints include urodynamic parameter, urinary incontinence, anorectal function, pelvic function, quality of life (QOL), disease-free survival and adverse events. Primary endpoint analyses will be carried out by Cochran-Mantel-Haenszel tests taking into center effect.DiscussionTo our knowledge this is the first trial to investigate the effect of TENS treatment on bladder function recovery after RH III among CC patients. This study will provide new information on TENS efficacy for bladder function recovery. Once confirmed, it may help to provide a new, non-invisive treatment for those postoperative CC patients with poor pelvic function, which would help improve their quality of life.Trial registrationThe study is registered to Clinical Trials.gov (NCT02492542) on June 25, 2015.

show abstract

A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction

Cited by 42 publications

References 85 publications

Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease

Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease

Managing overactive bladder in primary care

Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial

Contact Info

Product

Resources

About